Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) just unveiled an announcement.
Charmacy Pharmaceutical Co., Ltd. has called its annual general meeting for 22 May 2026 in Guangzhou, where shareholders will vote on the board and auditor reports and the audited financial statements for the year ended 31 December 2025. The meeting will also consider approval of the 2025 profit distribution plan and final dividend, as well as directors’ remuneration for 2026 and the reappointment of Pan-China Certified Public Accountants LLP as auditor.
Shareholders will further be asked to approve a comprehensive revolving credit line of up to RMB2.8 billion for the company and its subsidiaries, authorizing the president to handle related procedures and guarantees. In addition, the board is seeking a general mandate to issue up to 20% of the company’s existing share capital and to amend the articles of association accordingly, a move that could enhance financial flexibility but also has potential dilution implications for existing investors.
More about Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. is a PRC-incorporated pharmaceutical company listed in Hong Kong, operating in the drug and healthcare distribution sector. The group provides pharmaceutical products and related services in mainland China, positioning itself within the broader Chinese healthcare and pharmaceutical supply chain market.
Average Trading Volume: 2,750
Technical Sentiment Signal: Sell
Current Market Cap: HK$628.6M
For a thorough assessment of 2289 stock, go to TipRanks’ Stock Analysis page.